The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID ‐19 in the capital region of Denmark
Authors' conclusion
Among those hospitalized for COVID-19, patients with T2D did not have a higher risk of death and ICU admission, when adjusting for confounders.
Study context
- Population
- Patients hospitalized with confirmed COVID-19, Capital Region of Denmark, 1 March 2020 to 1 December 2021analysed
- Participants
- 4,430 patients
- Exposure
- T2D vs no diabetes
- T2Dn = 1,236
- Without diabetesn = 2,194reference
- Outcome
- 30-day mortality and ICU admission
- Follow-up
- 30 days
Methodological detailsCox proportional hazards models adjusted for available confounders, electronic health record data
- Cox proportional hazards models adjusted for available confounders
- Electronic health record data
Main finding
As reported in the abstract
T2D vs Without diabetesEstimate (95% CI)
Mortality
aHR 1.13(0.95–1.33)
ICU admission
aHR 1.01(0.79–1.29)
Mortality, crude
HR 1.37(1.19–1.58)
ICU admission, crude
HR 1.28(1.04–1.57)
- Overall 30-day mortality
- 19% (n = 850)
- Overall intensive care unit (ICU) admission
- 10% (n = 421)
Observational data: associations, not effects.
Further findings
Baseline haemoglobin A1c (HbA1c) and glucose-lowering medication in T2D
- Neither baseline HbA1c nor specific glucose-lowering medication use were significantly associated with the outcomes
Original publication
The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID ‐19 in the capital region of Denmark. Diabetes Obes Metab. Published 5 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →